Titlebook: Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Ag; Proceedings of the N Joel Morganroth,

inquisitive

諷刺滑稽戲劇

Omnipotent

What do New Cardiovascular Agents (e.g. Antiarrhythmic Drugs) Have to Show to Establish a Favorable lude documentation of symptomatic relief in patients with troublesome symptoms and/or documentation of the prevention or reduction of clinical complications associated with arrhythmias (eg. sudden cardiac death) and, moreover, evidence of safety and tolerability. The evaluation of antiarrhythmic com

不能約

的’

Pitfalls in the Design and Evaluation of Clinical Trials of Intravenously Administered Cardiovasculaikely. Similarly, not all endpoints provide similarly strong evidence of efficacy. A clear distinction should always be made between endpoints that establish the . and those than establish the . of a new drug, particularly when a surrogate endpoint is used as the primary measure of the utility of an experimental agent.

Derogate

What are the Overall Strategies for Post-Thrombolytic Care That Include Use of Angioplasty? agents. This new approach has important implications for overall strategies in the management of patients with myocardial infarction. The purpose of this paper is to address strategies for post-thrombolytic care that use mechanical recanalization in an attempt to enhance the outcome of thrombolysis alone.

舞蹈編排

Thrombolytic Agents: Biologic Properties and Issues Regarding Products Derived by Recombinant DNA Tes which constitute a hazard: thrombosis. Counterbalancing this potential danger is the fibrinolytic system which destroys fibrin deposits. In this respect, fibrin deposition may be considered a fundamental mechanism of injured tissue repair and fibrinolysis (thrombolysis) its physiologic antithesis.

長處

What do New Cardiovascular Agents (e.g. Antiarrhythmic Drugs) Have to Show to Establish a Favorable ations associated with arrhythmias (eg. sudden cardiac death) and, moreover, evidence of safety and tolerability. The evaluation of antiarrhythmic compounds is complex and several methodological issues need to be considered.

Explicate

節(jié)省

The Relative Benefit and Risks of Intravenous Streptokinase and Tissue Plasminogen Activator in Acutive reperfusion rates, complication rates and clinical efficacy. In part the debate exists because: a) there is a dramatic price difference separating the two drugs; b) the market share (stakes) are substantial; and c) the ultimate arbiter, i.e. direct comparative data, is thus far limited.